Advertisement
YOU ARE HERE: LAT HomeCollectionsHuman Immuno Deficiency Virus
IN THE NEWS

Human Immuno Deficiency Virus

WORLD
June 28, 2007 | From Times Wire Reports
A Kazakh court convicted 21 medical workers of having roles in infecting scores of children with HIV. The Shymkent district court gave suspended sentences to five senior health officials, including the district's chief medical officer, according to the ruling by Judge Ziyadinkhan Pirniyaz. Sixteen other medical workers, including nurses and doctors in the city's hospital and clinics, received sentences of up to five years.
Advertisement
SCIENCE
June 23, 2007 | From Times Staff and Wire Reports
Pfizer Inc., the world's biggest drug maker, failed to win U.S. approval for maraviroc, the first new type of medicine in a decade to treat HIV, the virus that causes AIDS. Pfizer is working on changes the Food and Drug Administration sought on the product's labeling, the company said Wednesday. Maraviroc is intended for patients who have failed to reduce their levels of HIV with other treatments.
SCIENCE
June 23, 2007 | Amber Dance, Times Staff Writer
Humans may lack resistance to HIV in part because a potentially defensive protein is still guarding against a long-extinct virus, scientists reported Friday. Researchers have known that some primates, such as macaques, can fight off HIV with an antiviral protein called TRIM5-alpha, whereas the human version, though only slightly different, cannot combat HIV. Scientists at the Fred Hutchinson Cancer Research Center in Seattle wondered just what virus the human protein was able to attack.
NATIONAL
May 31, 2007 | James Gerstenzang, Times Staff Writer
President Bush said Wednesday that he would ask Congress to increase U.S. support for the global fight against HIV/AIDS to $30 billion over five years from the current commitment of $15 billion. The White House estimates the increased spending would treat 2.5 million people, prevent 12 million infections and provide additional care for 12 million people, among them 5 million orphans and other children. In the program's first three years, through March, it helped pay for treatment of 1.
NATIONAL
May 9, 2007 | From Times Wire Reports
Former President Clinton announced agreements with drug companies to lower the price of "second-line" AIDS drugs for people in the developing world and to make a once-a-day AIDS pill available for less than $1 a day. The anti-retroviral drugs are needed by patients who develop resistance to first-line treatment and cost 10 times as much as first-line therapy, Clinton said in New York. Nearly half a million will require these drugs by 2010.
BUSINESS
April 25, 2007 | From the Associated Press
The federal government should approve a novel drug that targets the cells of HIV-infected patients and not the virus itself, health advisors recommended Tuesday. The 12 advisors unanimously voted to urge the Food and Drug Administration to approve maraviroc, which Pfizer Inc. hopes to sell under the brand name Celsentri. It would represent the first so-called CCR5 receptor antagonist to be sold.
SCIENCE
April 21, 2007 | Thomas H. Maugh II, Times Staff Writer
German researchers have found a peptide in human blood that blocks HIV and have identified a synthetic variant that is 100 times more potent, they reported Friday in the journal Cell. The synthetic version has been shown to be safe in animals and the team hopes to begin trials in humans this year, they said.
BUSINESS
April 21, 2007 | From Reuters
An experimental Pfizer Inc. AIDS pill was effective at suppressing the HIV virus when added to the best available drug regimens, U.S. drug reviewers said in an analysis released Friday. The Food and Drug Administration staff, however, said they would ask an advisory panel that meets Tuesday for advice "regarding the possible need for special labeling as well as whether additional clinical trials should be performed to address particular safety issues."
SCIENCE
April 5, 2007 | Jia-Rui Chong, Times Staff Writer
A new AIDS drug that received accelerated federal approval last summer is significantly better at attacking highly resistant HIV than existing drugs, according to a study of 230 patients published Wednesday. Darunavir, part of the decade-old class of drugs known as protease inhibitors, lowered virus levels to the undetectable range in 45% of patients after 48 weeks. By comparison, 10% of patients on other drug regimens showed similar declines.
CALIFORNIA | LOCAL
April 4, 2007 | Jordan Rau, Times Staff Writer
A widely touted law that was supposed to provide medical care for poor, uninsured Californians infected with HIV has yet to be put into practice by Gov. Arnold Schwarzenegger's administration, leaving thousands without the health coverage lawmakers promised more than four years ago. The 2003 law was endorsed by newspapers across the state and championed by activists as the most significant piece of AIDS-related legislation in a decade.
Los Angeles Times Articles
|